Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Drops By 34.1%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totaling 101,823 shares, a decrease of 34.1% from the December 31st total of 154,542 shares. Based on an average daily trading volume, of 75,470 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.5% of the shares of the company are short sold. Approximately 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 75,470 shares, the days-to-cover ratio is presently 1.3 days.

Institutional Trading of Calidi Biotherapeutics

An institutional investor recently bought a new position in Calidi Biotherapeutics stock. Warberg Asset Management LLC bought a new position in shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 18,705 shares of the company’s stock, valued at approximately $28,000. Warberg Asset Management LLC owned approximately 0.55% of Calidi Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 12.53% of the stock is currently owned by institutional investors and hedge funds.

Calidi Biotherapeutics Stock Performance

Shares of NYSEAMERICAN CLDI traded down $0.03 during mid-day trading on Friday, reaching $1.02. 89,792 shares of the company traded hands, compared to its average volume of 74,493. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.12 and a quick ratio of 2.12. Calidi Biotherapeutics has a fifty-two week low of $0.97 and a fifty-two week high of $19.20. The stock has a fifty day simple moving average of $1.25 and a 200-day simple moving average of $2.35.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($2.21) earnings per share (EPS) for the quarter. Analysts anticipate that Calidi Biotherapeutics will post -4.48 EPS for the current fiscal year.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.